Sihuan Pharmaceutical (HKG:0460) expects to record a maximum loss of 600 million yuan and a minimum revenue of 1.80 billion yuan for 2024, a Monday bourse filing said.
The company attributed its financial results for the reporting year to a decline in its generic drug business, high research and development costs for its innovative drugs, and certain one-off expenses.